PRELUDE THERAPEUTICS INC (PRLD)

US74065P1012 - Common Stock

1.24  -0.06 (-4.62%)

After market: 1.2 -0.04 (-3.23%)

PRELUDE THERAPEUTICS INC

NASDAQ:PRLD (12/23/2024, 10:34:00 PM)

After market: 1.2 -0.04 (-3.23%)

1.24

-0.06 (-4.62%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%4.44%
Sales Q2Q%N/A
CRS3.35
6 Month-67.45%
Overview
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)02-13 2025-02-13/amc
Ins Owners8.97%
Inst Owners54.82%
Market Cap68.25M
Shares55.04M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts76.36
Short Float %11.14%
Short Ratio7.78
IPO09-25 2020-09-25
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PRLD Daily chart

Company Profile

Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. The company is headquartered in Wilmington, Delaware and currently employs 128 full-time employees. The company went IPO on 2020-09-25. The company has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.

Company Info

PRELUDE THERAPEUTICS INC

175 Innovation Boulevard

Wilmington DELAWARE 19803

P: 13024671280

CEO: Krishna Vaddi

Employees: 128

Website: https://preludetx.com/

PRLD News

News Image13 days ago - Prelude Therapeutics, IncorporatedPrelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
News Image13 days ago - Prelude Therapeutics, IncorporatedPrelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

• PRT2527 demonstrated activity across a range of relapsed/refractory lymphoid malignancies, including patients who received prior CAR-T therapy •...

News Imagea month ago - Prelude Therapeutics, IncorporatedPrelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
News Imagea month ago - Prelude Therapeutics, IncorporatedPrelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

WILMINGTON, Del., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology...

News Image2 months ago - Prelude Therapeutics, IncorporatedPrelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
News Image2 months ago - Prelude Therapeutics, IncorporatedPrelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

PRLD Twits

Here you can normally see the latest stock twits on PRLD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example